Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.

• Tác giả: Liliana Antunes, Sabrina Bacci, Luca Basile, Maria-Louise Borg, Jesús Castilla, Roisin Duffy, Ralf Dürrwald, Aušra Džiugytė, Margaret Fitzgerald, Verónica Gomez, Carolin Hackmann, Jennifer Howard, Petr Husa, Ligita Jancoriene, Monika Kuliese, Mihaela Lazar, Isabel Leroux-Roels, Marcos Lozano, Ausenda Machado, Zvjezdana Lovrić Makarić, Alexandru Marin, Iván Martínez-Baz, Nathalie Nicolay, Beatrix Oroszi, Goranka Petrović, Madelyn Rojas-Castro, Angela M C Rose, Lenka Součková, Silke Ternest, Gergő Túri, Nuno Verdasca
• Ngôn ngữ: eng
• Thông tin xuất bản: England : Influenza and other respiratory viruses , 2025
• Bộ sưu tập: NCBI
• ID: 693464

Tóm tắt

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.